Table 1.

Characteristics of the Study Cohort

Characteristics	Study Cohort (N=660)
Age at diagnosis, mean (SD), years	56.9 (18.1)
Sex, female, n (%)	392 (59.4)
Race, n (%)
White	559 (84.7)
Black	18 (2.7)
Other	21 (3.2)
Unknown	62 (9.4)
Ethnicity, n (%)
Non-Hispanic	598 (90.6)
Hispanic	33 (5.0)
Unknown	29 (4.4)
AAV Disease Characteristics
Baseline BVAS/WG Score, mean (SD)	4.4 (2.2)
ANCA Type, n (%)
PR3-ANCA+	268 (41%)
MPO-ANCA+	392 (59%)
Renal Involvement, n (%)
Any Renal Disease	411 (63%)
End-Stage Renal Disease Ever	105 (16%)
Duration of follow-up, median (IQR), months	118 (61-180)
Prior to the initial treatment	34 (10-69)
After the initial treatment	61 (22-124)
Clinical notes, n (%)
Prior to the initial treatment	14 637 (12.9)
After the initial treatment	98 411 (87.1)

SD: Standard Deviation; IQR: Interquartile range;